Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis

Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy

(2019) Sonja Althammer et al.   Journal for ImmunoTherapy of Cancer

Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods

(2018) Kelly A. Schats et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay

(2018) Paul Scorer et al.   Diagnostic Pathology

Deep Semi Supervised Generative Learning for Automated Tumor Proportion Scoring on NSCLC Tissue Needle Biopsies

(2018) Ansh Kapil et al.   Scientific Reports

Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung Cancer

(2017) Reinhard Büttner et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors

(2017) Antonio Marchetti et al.   Journal of Thoracic Oncology

PL04a.03: Durvalumab in ≥3rd-Line Locally Advanced or Metastatic, EGFR/ALK Wild-Type NSCLC: Results from the Phase 2 ATLANTIC Study

(2017) Marina Garassino et al.   Journal of Thoracic Oncology

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

(2017) Fred R. Hirsch et al.   Journal of Thoracic Oncology

PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability

(2017) Hans Brunnström et al.   MODERN PATHOLOGY

PD-L1 and Lung Cancer: The Era of Precision-ish Medicine?

(2016) Alain C. Borczuk et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma

(2016) Marlon C. Rebelatto et al.   Diagnostic Pathology

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer

(2016) Charlotte Roach et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

3090 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or recurrent non-small-cell lung cancer progressing after platinum-based chemotherapy: A phase Ib trial

(2015) J.L. Gulley et al.   EUROPEAN JOURNAL OF CANCER

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer

(2015) Therese Phillips et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

(2015) Luisa Carbognin et al.   PLoS One

Automated Analysis and Detailed Quantification of Biomedical Images Using Definiens Cognition Network Technology®

(2009) Martin Baatz et al.   COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING